UNSPSC 51284716: Tiamulin hydrogen fumarate

This classification denotes an antibiotic with the molecular formula C28H47NO4S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ION1Q02ZCX, chemically known as acetic acid, ((2-(diethylamino)ethyl)thio)-, 6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3-alpha,9-propano-3-alpha-h-cyclopentacycloocten-8-yl ester, (e)-2-butenedioate (1:1) (salt) but more generally known as tiamulin fumarate, which bears US NIH Compound Identifier 6434500.

Most nations, for tariff and trade purposes, schedule tiamulin hydrogen fumarate under HS 29419000. SMILES: CCN(CC)CCSCC(=O)O[C@@H]1C[C@@]([C@H]([C@@H]([C@@]23CC[C@H]([C@@]1([C@@H]2C(=O)CC3)C)C)C)O)(C)C=C.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51284716 Tiamulin hydrogen fumarate is a Commodity code that nominally addresses a specific veterinary antibiotic, but the recent state and local procurement activity tagged under this code shows minimal alignment with that pharmaceutical scope. The opportunities on record involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, emergency medical and first aid supplies, and generic multi-source pharmaceuticals and over-the-counter products — none of which are tiamulin hydrogen fumarate. The mismatch suggests either systematic miscoding by issuing bodies or that this UNSPSC designation is not actively used by state and local procurement offices for its nominal product category.

The geographic activity appears scattered across Florida, Texas, Minnesota, and Oregon based on the four recent opportunities, but the lack of coherent solicitations under the actual code scope limits any meaningful characterization of repeat buyers or regional concentration. Seminole County, Florida issued an IFB (No. IFB60459723LAS) in June 2026 for naloxone and drug deactivation systems with a July 26, 2023 response date; the City of Tampa issued an IFB (No. 26P00145) in March 2026 for medical and first aid supplies with a March 13, 2026 response date and an estimated contract value of $700,000 with a sheltered small local business enterprise set-aside; the Texas Health and Human Services Commission issued an RFI (No. HHS0017013) in April 2026 for direct-to-manufacturer prescription program capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (No. S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The code shows little relevant recent activity and should be deprioritized unless your firm specializes in tiamulin hydrogen fumarate procurement for livestock or other veterinary applications, in which case you should investigate whether state and local animal health or agriculture departments are using this code correctly.